The FDA has issued warning letters to multiple companies marketing compounded Retatrutide, an investigational drug from Eli Lilly still in Phase II trials. While early studies have shown promising weight loss results, Retatrutide FDA Warning Letter to Neil R. Feins, M.D. 2009 05 20 Circare On August 15 2025, the U.S. Food & Drug Administration (FDA) issued a Warning Letter to Platinum Biologics LLC for marketing umbilicalcordderived products including exosome products (NanoEx & Nano Xsomes) without approval. FDA to weigh easing limits on unproven peptides favored by RFK Jr. and MAHA supporters PBS News Is BPC 157 Banned? Oral vs. Injectable Forms Explained BPC 157 penis enlargement: What the evidence and real world experience actually show